What must be proved in an informed-consent claim?

Facts and context

Eleven-year-old Angelica Soliman was diagnosed with osteosarcoma, a highly malignant bone cancer. After her right leg was amputated, surgeon Dr. Jaime Tamayo referred her to medical oncologist Dr. Rubi Li for adjuvant chemotherapy. Angelica received cisplatin, doxorubicin, and Cosmegen at St. Luke’s Medical Center. She developed rashes, falling blood counts, bleeding, and other complications, and died eleven days after the first chemotherapy cycle.

Angelica’s parents alleged that Dr. Li had assured them of a 95% chance of healing and had disclosed only nausea, vomiting, hair loss, and weakness. Dr. Li testified that she had explained that chemotherapy could also reduce red cells, white cells, and platelets and could damage organs. The medical records were not produced at trial, so the dispute about disclosure and monitoring turned largely on testimony. The parents pursued both negligent-treatment and lack-of-informed-consent theories.

Issue

Did the parents prove the distinct elements of an informed-consent claim: a duty to disclose material risks, inadequate disclosure, consent that would have been withheld with proper information, and an injury produced by the undisclosed risk? Did the evidence separately establish negligent chemotherapy care?

Ruling and doctrine

The Court granted Dr. Li’s petition and dismissed the claim. The majority concluded from the testimonial record that the material side effects had been discussed and that the parents had not established the elements required for liability based on lack of informed consent. It also found the proof insufficient to attribute Angelica’s death to negligent administration or monitoring by Dr. Li.

The case distinguishes a disclosure claim from a claim that treatment was performed negligently. Each requires its own evidence. Separate opinions disagreed with aspects of the majority’s treatment of causation and disclosure, so those opinions should not be presented as the Court’s controlling holding.

Practice implications

Parao Law practice guidance

For physicians

• Explain the proposed treatment, its purpose, expected benefit, material risks, and reasonable alternatives, including declining treatment where relevant.
• Identify the decision-maker. For a child, confirm the appropriate parent or representative’s authority and communicate in understandable terms; do not treat the child’s inability to consent as permission to omit the discussion.
• Invite questions and check understanding. Ask the decision-maker to describe the main benefit, serious risks, and alternatives in their own words.
• Document what was actually disclosed, the questions asked, who participated, and the decision. Keep the discussion record with the appropriate consent documentation.
• If the proposed treatment materially changes, assess whether further explanation and consent are needed; do not assume an earlier signature answers a new decision.

For lawyers

• Structure the claim around duty to disclose, inadequate disclosure, a treatment decision adequate disclosure would have changed, and injury caused by treatment.
• Specify the undisclosed information and why it was material. Obtain consent forms, contemporaneous notes, explanatory materials, and testimony about the discussion.
• Address decision causation and medical causation separately. Evidence that a parent did not know a risk does not, alone, prove that disclosure would have changed the decision or that treatment caused the injury.
• Distinguish the majority from concurring and dissenting opinions. Cite the opinion supporting the proposition rather than presenting the dissent as the holding.

Limits of the ruling

Li does not supply a universal consent script or settle the disclosure requirements for every treatment. The record, the type of information in dispute, and the majority’s reasoning matter. This reading offers an analytical structure, not a contemporary chemotherapy protocol.